What is Pulmonary alveolar proteinosis?
Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by the abnormal accumulation of surfactant-like proteins and lipids in the air sacs (alveoli) of the lungs. This buildup interferes with normal gas exchange, leading to progressive breathing difficulties and reduced oxygen levels in the blood. PAP affects approximately 3.7 people per million globally, with most cases being autoimmune in nature, caused by antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). While considered a serious condition, many patients can achieve significant improvement with appropriate treatment and management.
Key statistics
| Prevalence | 3.7 per million people worldwide |
| Age of onset | Typically 20-50 years, peak in 30s-40s |
| Gender ratio | Male-to-female ratio approximately 2:1 |
| Mortality | 5-year survival rate >95% with treatment |
Symptoms
Progressive shortness of breath, fatigue, persistent cough, reduced exercise tolerance, chest discomfort.
The hallmark symptom of PAP is **progressive dyspnea** (shortness of breath) that develops gradually over months to years. Patients typically first notice difficulty breathing during physical activity, which progressively worsens to affect daily activities and eventually occurs at rest. **Fatigue** is another prominent early symptom, often described as overwhelming tiredness that doesn’t improve with rest.
A **persistent, dry cough** is common, sometimes producing small amounts of thick, white sputum. Many patients experience **reduced exercise tolerance**, finding themselves unable to maintain their previous level of physical activity. **Chest discomfort** or tightness may occur, though severe chest pain is uncommon.
As the condition progresses, patients may develop **hypoxemia** (low blood oxygen levels), which can cause bluish discoloration of the lips or fingernails (cyanosis). Some patients experience **weight loss** and **general malaise**. Fever is typically absent unless a secondary infection develops.
Causes and risk factors
PAP is primarily an autoimmune condition caused by antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF). These anti-GM-CSF antibodies interfere with the normal function of alveolar macrophages, the immune cells responsible for clearing surfactant from the lungs. When these macrophages cannot function properly, surfactant-like material accumulates in the alveoli.
There are three main types of PAP: **autoimmune PAP** (90% of cases), caused by anti-GM-CSF antibodies; **hereditary PAP**, caused by genetic mutations affecting surfactant production or clearance; and **secondary PAP**, which occurs in association with other conditions such as hematologic malignancies, immunodeficiency disorders, or exposure to certain dusts (particularly silica).
Risk factors for developing autoimmune PAP are not well understood, as it typically occurs in previously healthy individuals. Secondary PAP risk factors include exposure to silica dust, aluminum dust, or titanium dioxide, as well as having blood cancers or immune system disorders.
Prevention
There is no known prevention for autoimmune PAP, as it develops spontaneously without identifiable triggers. For hereditary forms, genetic counseling may be beneficial for families with known mutations. Secondary PAP prevention focuses on avoiding known occupational exposures such as silica dust and maintaining good management of underlying conditions that may predispose to the disease.
Regular health monitoring and prompt treatment of respiratory infections may help prevent complications in those already diagnosed. Smoking cessation is strongly recommended, as smoking can worsen lung function and increase infection risk.
Complications
Without treatment, PAP can lead to progressive respiratory failure as surfactant accumulation worsens gas exchange. The most serious complication is **secondary pulmonary infections**, which occur in approximately 13% of patients. These infections can be bacterial, fungal, or opportunistic, with Nocardia and other unusual pathogens being particular concerns.
**Pulmonary hypertension** may develop due to chronic hypoxemia and lung damage. Some patients experience **pneumothorax** (collapsed lung), though this is less common. **Progressive pulmonary fibrosis** can occur in severe, long-standing cases, leading to permanent lung damage.
Untreated PAP can result in severe disability due to respiratory limitation and, in extreme cases, can be life-threatening due to respiratory failure or severe infections.
Diagnosis
PAP diagnosis typically begins with **high-resolution computed tomography (HRCT)** of the chest, which shows the characteristic “crazy-paving” pattern – a combination of ground-glass opacification with superimposed interlobular septal thickening. This imaging finding, while not unique to PAP, is highly suggestive when present in the appropriate clinical context.
**Serum GM-CSF autoantibody testing** is crucial for confirming autoimmune PAP and is positive in over 95% of cases. **Arterial blood gas analysis** typically reveals hypoxemia with an increased alveolar-arterial oxygen gradient.
**Bronchoalveolar lavage (BAL)** produces characteristic milky fluid that appears thick and turbid. BAL fluid analysis shows **PAS-positive** (periodic acid-Schiff) material and elevated **surfactant proteins**, particularly SP-A and SP-D. **Lung biopsy** is rarely necessary but may be considered in atypical cases, showing alveoli filled with eosinophilic, PAS-positive proteinaceous material.
Additional tests include **pulmonary function testing**, which typically shows reduced diffusion capacity (DLCO) and may reveal restrictive patterns in advanced disease.
Treatment
The gold standard treatment for PAP is **whole lung lavage (WLL)**, a procedure performed under general anesthesia where one lung is repeatedly filled with saline and drained to wash out accumulated surfactant material. This procedure can provide significant improvement in symptoms and oxygenation lasting 15 months to several years.
**GM-CSF supplementation** has shown promise as an alternative or adjunctive treatment. Sargramostim, a recombinant GM-CSF, can be administered subcutaneously or by inhalation and may help restore normal macrophage function.
**Rituximab**, a monoclonal antibody that targets B cells, has been used in some patients to reduce anti-GM-CSF antibody production, though evidence is still limited. Plasmapheresis may be considered in severe cases to remove circulating antibodies.
Supportive care includes **supplemental oxygen** for hypoxemic patients and **pulmonary rehabilitation** to improve exercise tolerance. **Infection prevention** through vaccinations (pneumococcal, influenza) is important, and prompt antibiotic treatment is essential for any respiratory infections.
Prognosis
The prognosis for autoimmune PAP is generally favorable with appropriate treatment. More than 95% of patients survive at least five years after diagnosis. Whole lung lavage provides symptomatic improvement in approximately 85% of patients, with effects lasting months to years.
Some patients experience **spontaneous improvement** without treatment, though this is unpredictable and uncommon (occurring in about 8% of cases). Most patients require periodic whole lung lavage procedures, typically every 1-3 years, though the frequency varies considerably between individuals.
Quality of life can be significantly improved with treatment, allowing many patients to return to near-normal activities. However, complete cure is rare, and most patients require ongoing monitoring and periodic interventions.
Quality of life
With proper treatment, many PAP patients can maintain good quality of life and continue working and participating in family activities. **Exercise tolerance** often improves significantly after whole lung lavage, allowing patients to resume many physical activities, though high-intensity exercise may remain limited.
**Sleep quality** can be affected by breathing difficulties, and some patients may benefit from sleep studies and continuous positive airway pressure (CPAP) therapy if sleep apnea is present. Maintaining a healthy diet rich in antioxidants may support overall lung health.
**Mental health** support is important, as living with a rare disease can be isolating and stressful. Connecting with other patients through support groups or online communities can provide valuable emotional support and practical advice.
Patients should avoid dusty environments and practice good respiratory hygiene. Regular gentle exercise, as tolerated, can help maintain cardiovascular fitness and respiratory muscle strength.
Pregnancy and fertility
PAP does not directly affect fertility, but the condition may complicate pregnancy due to increased oxygen demands and potential respiratory compromise. Pregnant women with PAP require close monitoring by both pulmonology and obstetrics specialists.
Whole lung lavage can be performed during pregnancy if necessary, though timing and anesthetic considerations require careful planning. GM-CSF supplementation use during pregnancy should be carefully evaluated, weighing benefits against potential risks to the fetus.
Genetic counseling is recommended for patients with hereditary PAP, as some forms follow autosomal recessive inheritance patterns.
Children
PAP in children is rare and more commonly represents hereditary forms due to genetic mutations affecting surfactant metabolism. Pediatric PAP may present with more severe symptoms and often requires more aggressive treatment.
Hereditary PAP in infants can be life-threatening and may require lung transplantation. Children with PAP need specialized pediatric pulmonology care and may require modifications to school activities based on their respiratory status.
When to see a doctor
Seek immediate medical attention for **severe shortness of breath**, **chest pain**, **fever with respiratory symptoms**, or **blue discoloration** of lips or fingernails. These symptoms may indicate respiratory failure or secondary infection requiring urgent treatment.
Schedule routine medical care for **progressive shortness of breath**, **persistent cough lasting more than three weeks**, **unexplained fatigue**, or **decreased exercise tolerance**. Early diagnosis and treatment can prevent complications and improve outcomes.
Regional context
Limited data exists on PAP prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or Eastern Mediterranean countries. The condition appears to affect all ethnicities equally, suggesting similar prevalence rates worldwide. Healthcare providers in these regions interested in contributing data on PAP cases are encouraged to contact Global Medical Journal to help build regional knowledge of this rare condition.
Research and clinical trials
Current research focuses on **automated whole lung lavage** systems to improve procedure efficiency and safety. **Inhaled GM-CSF formulations** are being studied to provide more convenient administration routes. **Novel therapeutic targets** including other cytokines and surfactant metabolism pathways are under investigation.
**Gene therapy approaches** are being explored for hereditary PAP, potentially offering curative treatments for genetic forms. Research into **biomarkers** for monitoring disease progression and treatment response is ongoing.
Patients interested in clinical trials should consult ClinicalTrials.gov and discuss options with their pulmonologists. The PAP Foundation maintains updated information about research opportunities and clinical trials.
Frequently asked questions
Is pulmonary alveolar proteinosis contagious?
No, PAP is not contagious. It is an autoimmune or genetic condition that cannot be transmitted from person to person through any means of contact.
How often will I need whole lung lavage procedures?
The frequency varies greatly between patients, ranging from every 6 months to every 3-4 years. Most patients require lavage every 1-2 years, depending on symptom severity and progression.
Can I live a normal life with PAP?
Many patients with PAP can maintain good quality of life with proper treatment. While some activity limitations may persist, most people can work, travel, and participate in family activities with appropriate management.
Will my children inherit PAP?
Autoimmune PAP (90% of cases) is not inherited. Only hereditary PAP, which is much rarer, can be passed to children. Genetic counseling can help assess individual risk based on your specific type of PAP.
Are there any dietary restrictions with PAP?
There are no specific dietary restrictions for PAP. However, maintaining a healthy, balanced diet rich in antioxidants may support overall lung health and immune function.
Support and resources
**PAP Foundation** (papfoundation.org) – Primary patient advocacy organization providing education, support, and research funding for PAP patients and families.
**National Organization for Rare Disorders (NORD)** (rarediseases.org) – Comprehensive information about rare diseases including PAP.
**Orphanet** (orpha.net) – European reference portal for rare diseases and orphan drugs.
**EURORDIS** (eurordis.org) – European rare disease patient advocacy alliance.
**Global Genes** (globalgenes.org) – Rare disease patient advocacy organization with resources for patients and families.
Related conditions
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Pulmonary alveolar proteinosis.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/pulmonary-alveolar-proteinosis/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?